This evidence-based review examines whether red or near-infrared photobiomodulation can treat early COVID-19. Human trials remain preliminary, device-specific, and insufficient to prove viral clearance or broad clinical benefit. It explains proposed mechanisms, intranasal delivery, measurement standards, safety, regulatory limits, and why proven antiviral care should take priority.